Managing ADHD Medication Adverse Events
A point-of-care reference for the adverse event in front of you. Each chapter takes one clinical problem on a stimulant or non-stimulant and works it through to a decision: continue, reduce, change the timing or formulation, switch, stop, or refer urgently.
How to Use This Course
This is a lookup course, not a read-through course. Every chapter title is the question you are trying to answer, so you can go straight from the patient's complaint to the chapter that settles it. Each chapter stands on its own.
- Start from the problem, not the drug. Chapters are organized by what the patient reports — chest pain, tics, insomnia, weight loss — so you do not need to know the cause before you look it up.
- Read the 60-Second Brief first. Every chapter opens with the decision and the reasoning behind it, short enough to read between patients.
- Check the urgent chapters before you need them. Overdose, psychosis or mania, cardiac symptoms, rebound hypertension and suicidal thinking on atomoxetine or viloxazine are the situations where there is no time to look things up.
- Use the capstone as your triage sheet. Chapter 20 pulls the stopping rules and dose-change rules from the whole course into one place.
- Follow the sources. Claims are tied to the label, guideline or study they come from, so you can check anything before you act on it.
Chapters by Section
Twenty chapters in five sections, starting with the emergencies. Select a section to see its chapters; each title opens the chapter.
Chapters 1–5 · When the question is how fast to act.
- Stimulant Overdose or Accidental Ingestion: When Is Emergency Evaluation Needed?
- Guanfacine, Clonidine or Other Non-Stimulant Overdose or Accidental Ingestion: When Is Emergency Evaluation Needed?
- New Psychosis or Mania During ADHD Treatment: When to Stop and Can You Rechallenge?
- Chest Pain, Palpitations or Syncope During ADHD Treatment: When to Stop and Refer Urgently?
- Rebound Hypertension After Stopping Guanfacine or Clonidine: How Urgently to Act?
Chapters 6–12 · The adverse effects you manage every week.
- Appetite Suppression, Weight Loss and Growth on ADHD Medication: When to Adjust Treatment?
- Insomnia After ADHD Medication: Change Timing, Dose or Formulation?
- Sustained Blood Pressure or Heart Rate Rise on ADHD Medication: When to Reduce or Stop? — FREE PREVIEW
- Anxiety or Panic on a Stimulant: Reduce, Change or Stop?
- Irritability, Wear-Off Rebound or Emotional Blunting: How Should the Stimulant Change?
- New or Worsening Tics During Stimulant Treatment: Continue, Reduce or Switch? — FREE PREVIEW
- Nausea, Abdominal Pain, Constipation or Headache on ADHD Medication: Adjust or Investigate?
Chapters 13–15 · Atomoxetine, viloxazine and the alpha-2 agonists.
Chapters 16–19 · Problems from how the medication is taken, combined or restarted.
- Suspected Misuse, Diversion or Substance-Use Relapse: Continue, Restrict or Stop?
- Uncommon Serious Reactions to ADHD Medication: Which Need Immediate Evaluation or Stopping?
- Suspected Drug-Interaction Toxicity: Which Medication to Hold or Stop?
- Adverse Effects After Missed Doses, Restarting or Switching Formulations: When to Retitrate?
Chapter 20 · The stopping rules and dose-change rules from the whole course in one place.
To let you answer one question quickly and defensibly when an ADHD medication causes a problem: does this patient continue, change, or stop — and how urgently?
Sustained Blood Pressure or Heart Rate Rise on ADHD Medication
Stimulants, atomoxetine and viloxazine can raise blood pressure or heart rate. This chapter covers what the labels report, how to confirm a real rise before acting, which readings need the emergency department, and when to reduce, switch or stop. Draws on NICE, the AAP pediatric guideline and the 2025 AHA/ACC high blood pressure guideline for adults. Full chapter — no signup required.
New or Worsening Tics During Stimulant Treatment
Tics are common in children with ADHD and wax and wane on their own, which makes it hard to tell whether the stimulant is to blame. This chapter covers what the labels say, what the placebo-controlled trials and the Cochrane review found, how to judge whether the stimulant is responsible, and when to continue, reduce, switch or stop. Full chapter — no signup required.
Join Psychiatry Education Forum Academy
Unlock all 20 chapters of this course, the rest of the Rapid-Decision adverse events series, and the full Academy clinical reference library.
Monthly and annual plans available. Discounts for residents and students. Cancel anytime.
Responses